Replies to post #229385 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

Very Promising

Falconer- you have any thoughts regarding the possibility that 2-73 could Treat retinal diseases and blindness?

I was not aware of this article; or even the evidence supporting the role of the sigma-1 receptor protein in retinal health. Thanks for posting this.

The entire article is here:
https://www.ncbi.nlm.nih.gov/m/pubmed/30075336/

Check not only the abstract, but the titles of the Similar Articles in the right column. Even more indications of sigma-1 receptor protein involvement in retinal health.

This topic needs --- to start --- examination in animals. The retinas of lab rats and mice ("murines") are functionally identical to ours. If blarcamesine (Anavex 2-73) can protect or restore murine retinas, very high probability it will do that in humans, too.

As I've so often previously contended, I'm certain that Anavex Life Sciences Corp has privately commissioned any number of murine studies of their sigma-1 receptor agonists for a diversity of diseases and conditions; not just the three central nervous system diseases presently in human clinical trials.

I anticipate that after Anavex gains regulatory approval to market blarcamesine against an initial CNS disease (very likely Rett syndrome), the company will announce their findings of efficacies against an expanding diversity of diseases, not just those of the central nervous system. Treatment of retinal pathologies would be significant --- and not at all out of the question.